Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. Analysts anticipate that Neurocrine Biosciences will post 4.28 EPS for the current year.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

After hours: March 12 at 6:24:06 PM EDT Loading Chart for NBIX ...